Evidence Hub

The use of a complex preparation of alpha-interferon and first-phase immune-response cytokines--leukinferon

Gruzdeva TA, Kuznetsov VP, Beliaev DL, Vakhman IS, Fedorova NV, Babaiants AA, Polikarpova EV

Zhurnal mikrobiologii, epidemiologii i immunobiologii, 1994

Abstract

Cases of successful treatment of severe neurological complications, developing as a consequence of diphtheria intoxication, by injections of leukinferon, a new combined preparation of alpha-interferon and other cytokines of the first stage of immune response, are described. Toxico-allergic polyneuropathy with sensory, reflex, motor (tetraparesis) disturbances and the bulbar syndrome developed in males after nasopharyngeal diphtheria. For the first time effective and rapid therapy of the bulbar syndrome and other disturbances, developing in connection with the demyelinating toxico-allergic process, was shown to be possible due to the use of leukinferon in combination with other therapeutic measures. The preparation proved to be highly effective in the treatment given with a view to arrest the development of intercurrent infectious complications in severely ill, bedridden patients receiving prednisolone. Leukinferon produces a pronounced effect even in patients receiving massive doses of corticosteroids, thus making it possible to shortly abolish the use of these preparations.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free